Multifunctional high boron content MOFs nano-co-crystals for precise boron neutron capture therapy for brain glioma in situ. (August 2022)

• Record Type: Journal Article
• Authors: Wang, Zhijie; Chen, Ziteng; Zhang, Zizhu; Li, Jiacheng; Chen, Kui; Liang, Haojun; Lv, Linwen; Chang, Yannan; Liu, Sen; Yang, Wenjiang; Yang, Zhi; Yuan, Hui; Meng, Xiangxi; Liu, Tong; Wang, Feng; Li, Juan; Xing, Gengmei
• Is Part Of: Nano today. Volume 45(2022)
• Publication Date: 2022-08
• Subjects: Zirconium -- Porphyrin -- Metal-organic framework -- Nano-co-crystals -- Boron neutron capture therapy -- Glioma; Nanotechnology -- Periodicals; Nanosciences -- Périodiques; 620.505
• DOI: 10.1016/j.nantod.2022.101558
• Languages: English
• ISSNs: 1748-0132

Abstract

Abstract: Multifunctional high boron content MOFs nano-co-crystals were assembled and architected for precise boron neutron capture therapy (BNCT) of brain glioma. Zirconium and mesotetra(4-carboxyphenyl)porphyrin are screened and determined to structure stable (Zr-TCPP) MOFs. The MOFs binding boron acids formed 100.20 ± 6.72 nm co-crystal structures (MNCs), which contained 42.50 % boric acid (m/m), had excellent stability, superior colloid dispersion, and excellent biocompatibility. Importantly, they could cross the brain-blood barrier, selectively target brain tumors, and deliver a high boron dose of 67.50 ± 4.20 µg [ 10 B] g −1 . Inductively coupled plasma mass spectrometry showed an excellent tumor-to-normal tissue boron ratio of 6.20 ± 0.90 and tumor-to-blood boron ratio of 3.80 ± 0.35. The MNCs also had intrinsic fluorescence and Zr 89 positron emission tomography imaging capabilities, which can accurately trace and quantify MNCs in vitro and in vivo . Therefore, a significantly antitumor efficiency was achieved in BNCT for glioma in model mice by imaging location of precise space-time. Graphical Abstract: ga1 Highlights: ● Through design, screening and optimization, the MOFs nano co-crystals (MNCs) for boron neutron therapy (BNCT) were obtained. ● A strategy to synthesize MOFs using 89 Zr as a precursor was proposed to achieve positron emission tomography (PET) imaging of MNCs in vivo . ● The MNCs had capabilities to cross the blood-brain barrier, target and accumulate sufficient boron in the tumor. ● The MNCs can track the boron carrier's distribution in real-time by PET and fluorescence imaging to match the neutron beam for precise BNCT. ● The MNCs showed significant antitumor efficacy in the orthotopic glioma mice models by precise BNCT.